Aveta Biomics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.avetabiomics.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Aveta Biomics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06011109
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Treatment of Recurrent GBM With APG-157 Via Expanded Access
- Conditions
- GlioblastomaGlioblastoma Multiforme
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Aveta Biomics, Inc.
- Registration Number
- NCT05551013
Safety and Efficacy of APG-157 in Head and Neck Cancer
Phase 2
Recruiting
- Conditions
- Head and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of the Oropharynx
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Aveta Biomics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05312710
- Locations
- 🇺🇸
VAGLAHS, West Los Angeles, Los Angeles, California, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
News
No news found